Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Products Face Costlier Process Under Europe’s New MDD – Alcon Exec

This article was originally published in The Gray Sheet

Executive Summary

The combination product policy outlined in the proposed revisions to Europe's Medical Devices Directive is emerging as a leading industry concern

You may also be interested in...



European Device Reclassifications Are Burdensome, Trade Groups Say

Comments from AdvaMed and its European counterpart Eucomed raise concerns about device reclassifications appearing in the revised Medical Devices Directive

MDD Revision Clarifies Existing Policies, Tightens Industry Loopholes

A draft revision of the European Medical Devices Directive would give manufacturers of implantable and Class III devices less leeway to avoid clinical evaluation requirements

Sanofi's Dupixent Cleared For Children With Atopic Dermatitis In EU

The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel